NASDAQ: AKRO
Akero Therapeutics Inc Stock Ownership - Who owns Akero Therapeutics?

Insider buying vs selling

Have Akero Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Scott A. GangloffChief Technology Officer2025-08-152,600$19.62
$51.01kBuy
Jonathan YoungChief Operating Officer2025-08-121,349$48.32
$65.19kSell
Jane HendersonDirector2025-08-123,000$7.01
$21.03kBuy
Jane HendersonDirector2025-08-123,000$47.46
$142.37kSell
Jonathan YoungChief Operating Officer2025-08-1212,500$21.10
$263.75kBuy
Jonathan YoungChief Operating Officer2025-08-1211,151$47.72
$532.14kSell
Andrew ChengPresident and CEO2025-08-1118,805$48.87
$918.91kSell
Andrew ChengPresident and CEO2025-08-1110,795$48.07
$518.92kSell
Andrew ChengPresident and CEO2025-08-11400$49.44
$19.77kSell
Timothy RolphChief Scientific Officer2025-08-0512,500$21.09
$263.63kBuy

1 of 22

AKRO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AKRO insiders and whales buy or sell their stock.

AKRO Shareholders

What type of owners hold Akero Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Versant Venture Capital VI LP8.47%6,749,283$332.27MInsider
Janus Henderson Group PLC8.45%6,738,556$331.74MInstitution
Apple Tree Partners IV LP7.31%5,830,203$287.02MInsider
Blackrock Inc7.25%5,779,412$284.52MInstitution
General Atlantic LP7.19%5,733,989$282.28MInstitution
Rtw Investments LP6.87%5,477,561$269.66MInstitution
Vanguard Group Inc5.68%4,529,628$222.99MInstitution
Price T Rowe Associates Inc5.66%4,509,325$221.99MInstitution
Aaron Royston4.96%3,954,858$194.70MInsider
Avoro Capital Advisors LLC4.39%3,500,000$172.31MInstitution

1 of 3

AKRO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AKRO74.92%25.08%Net BuyingNet Selling
ACLX50.50%49.50%Net SellingNet Selling
AAPG0.02%0.00%
ZLAB3.93%1.76%Net SellingNet Selling
MIRM51.49%48.51%Net SellingNet Selling

Akero Therapeutics Stock Ownership FAQ

Who owns Akero Therapeutics?

Akero Therapeutics (NASDAQ: AKRO) is owned by 115.54% institutional shareholders, 38.68% Akero Therapeutics insiders, and 0.00% retail investors. Versant Venture Capital VI LP is the largest individual Akero Therapeutics shareholder, owning 6.75M shares representing 8.47% of the company. Versant Venture Capital VI LP's Akero Therapeutics shares are currently valued at $317.42M.

If you're new to stock investing, here's how to buy Akero Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.